Developer docs
API playgroundTry for free, no card

Search company profiles

Oryon Cell Therapies

Full company profile

uuid00vqks3

Namestring
Oryon Cell Therapies
Legal namestring
Oryon Cell Therapies
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Oryon Cell Therapies is a privately held, clinical-stage biotechnology company headquartered in Belmont, Massachusetts, founded in 2020 by Ole Isacson, M.D., Ph.D. (Harvard Medical School professor and founding director of the Neuroregeneration Research Institute at McLean Hospital) and Nikola Kojic, M.D., Ph.D. The company is developing an autologous neuron replacement therapy for Parkinson's disease in which patient-derived blood cells are reprogrammed into induced pluripotent stem cells (iPSCs) and differentiated into midbrain dopaminergic neurons that are then surgically implanted into the post-commissural putamen. The autologous design is intended to eliminate the need for chronic immunosuppression, and the unilateral implantation approach used in early cohorts provides an internal control to address placebo effects.

The lead program is in an ongoing Phase 1b/2a clinical trial at Brigham & Women's Hospital/Harvard Medical School in collaboration with the Neuroregeneration Institute at McLean Hospital (Mass General Brigham). Interim data from the first five participants, reported in March 2026, showed 29%-62% reductions in OFF-state MDS-UPDRS Part III motor scores at 6-18 months, sustained improvement beyond six months, no serious adverse events, and DaT-SPECT imaging evidence of greater than a five-fold increase in dopaminergic signal in the transplanted putamen of one participant. Several participants also showed reduced levodopa equivalent daily dose, suggesting decreased dependence on dopamine-replacement medication.

Oryon is pre-revenue and has raised approximately $42 million in total equity and grant funding, including a $21 million Series A tranche closed in March 2026 co-led by Neuro.VC and Byers Capital. The company has no commercial product, no disclosed pricing, and no manufacturing-scale commercial operations; revenue, if any, would only follow regulatory approval and commercialization of the autologous cell therapy. Its go-to-market model is currently oriented around clinical trial execution at academic medical centers, scientific conference presentations, and peer-reviewed publications, with future commercialization expected to target movement disorder specialists at major US academic medical centers. The company had 1-10 employees as of the most recent reporting.

Short descriptiontext

Oryon Cell Therapies is a clinical-stage biotechnology company developing an autologous dopaminergic neuron replacement therapy for Parkinson's disease, derived from patient iPSCs and implanted into the putamen, currently in a Phase 1b/2a trial at Brigham & Women's Hospital.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersBelmont, United States
HQ citystring
Belmont
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
autologous cell therapy, neuron replacement therapy, Parkinson's disease treatment, regenerative medicine, iPSC-derived neurons
Industry3 codes
PRIMARYHLAAABAE
Stem Cell Therapies (MSC/iPSC/HSC-derived)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAGAI
Neural & Spinal Cord Regeneration
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
Product category
Cell Therapy
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Future Therapeutic Product Sales
TypeOne Time License
Description

Pre-revenue clinical-stage biotech company. Anticipated future revenue from commercialization of autologous neuron replacement therapy for Parkinson's disease following regulatory approval. Revenue model will likely involve selling cell therapy products directly to healthcare providers and academic medical centers.

vcaonline.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Oryon Cell Therapies develops an autologous neuron replacement therapy in which a patient's own blood cells are reprogrammed into induced pluripotent stem cells (iPSCs) and differentiated into midbrain dopaminergic neurons for implantation into the putamen to restore motor function in Parkinson's disease patients. The product eliminates the need for chronic immunosuppression and is currently being evaluated in a Phase 1b/2a clinical trial at Brigham & Women's Hospital.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Motor scores decreased 29%–62% from baseline at 6–18 months post-treatment in Phase 1b/2a trial
+3 more records
Product overview1 text field

Oryon Cell Therapies is a clinical-stage biotechnology company developing a single lead product - an autologous dopaminergic neuron replacement therapy for Parkinson's disease. The therapy involves deriving induced pluripotent stem cells (iPSCs) from the patient's own blood cells, differentiating them into midbrain dopaminergic neurons using proprietary methods, and implanting them directly into the putamen region of the brain to restore dopaminergic function and motor control. The company's technology emerged from 30 years of scientific advances in stem cell biology and neurosurgical techniques, including foundational Parkinson's disease research conducted at Harvard University and Mass General Brigham. The therapy is currently being evaluated in a Phase 1b/2a clinical trial at Brigham & Women's Hospital, with early data demonstrating 29%-62% motor score improvements and neuroimaging evidence of restored dopaminergic signaling.

Product and service1 record
1Autologous Dopaminergic Neuron Replacement Therapy (Lead Program)
CategoryCell therapy / regenerative medicine
Description

An autologous cell therapy in which a patient's own blood cells are reprogrammed into induced pluripotent stem cells (iPSCs) and differentiated into midbrain dopaminergic neurons for implantation into the post-commissural putamen. The therapy is intended for Parkinson's disease patients to restore dopaminergic signaling and motor function without the need for chronic immunosuppression, and is currently being evaluated in a Phase 1b/2a clinical trial at Brigham & Women's Hospital.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-23
Description

Oryon collaborates with the Neuroregeneration Institute at McLean Hospital, part of Mass General Brigham, for its clinical research program. The collaboration involves foundational Parkinson's disease research and current clinical trial execution. Penelope Hallett, Ph.D., Co-Director of the Neuroregeneration Research Institute, serves as principal investigator.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-23
Description

Phase 1b/2a clinical trial is being conducted at Brigham & Women's Hospital/Harvard Medical School for Oryon's lead autologous neuron replacement therapy program.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Sana Biotechnology is developing engineered cell therapies, including hypoimmune cell transplant approaches, with applications in neurological diseases. Although broader than Oryon's focused Parkinson's program, Sana's cell engineering platform and CNS ambitions make it a relevant comparable for autologous/allogeneic cell therapy platforms targeting the brain.

TypeEmerging player
Description

Neuron23 is developing precision medicines for Parkinson's disease, including a LRRK2 inhibitor currently in Phase 2. Oryon board member Adam Knight was Neuron23's founder/CEO. Neuron23 competes with Oryon for Parkinson's market share and partnership interest, though via a small-molecule route rather than cell replacement.

TypeDirect peer
Description

Prevail Therapeutics (acquired by Eli Lilly in 2020) develops AAV-based gene therapies for neurodegenerative diseases, including PR001 for Parkinson's disease associated with GBA1 mutations. It is a direct competitor addressing Parkinson's neuronal dysfunction via a different modality (gene therapy vs. cell replacement) but the same underlying therapeutic hypothesis.

TypeOthers
Description

Roche has invested in Parkinson's and broader neurodegenerative disease pipelines (including prasinezumab collaborations) and pursues both small-molecule and biologic CNS strategies. Roche represents a relevant large-pharma strategic partner/acquirer with deep neurology presence, rather than a direct competitor to Oryon's cell therapy.

TypeDirect peer
Description

Aspen Neuroscience is developing autologous iPSC-derived dopaminergic neuron replacement therapies (ANPD001) for Parkinson's disease. It directly competes with Oryon in the autologous iPSC approach for the same indication, targeting a similar patient population and neurosurgical delivery model.

TypeBroad incumbent
Description

Vertex Pharmaceuticals is advancing VX-880, an allogeneic stem cell-derived islet cell therapy, and is building broader cell therapy capabilities that could overlap with Oryon's CNS cell replacement vision. As a large, well-capitalized biopharma, Vertex represents both a competitive threat and a potential strategic acquirer/partnership candidate.

TypeEmerging player
Description

Cerevel Therapeutics (acquired by AbbVie in 2024) developed CNS therapies including Parkinson's disease candidates (e.g., tavapadon). As a CNS-focused clinical-stage biotech, Cerevel is a relevant comparable for fundraising scale, clinical development approach, and large-pharma acquisition interest in Parkinson's assets.

TypeBroad incumbent
Description

Acorda Therapeutics developed and commercialized INBRIJA and other Parkinson's therapies; Oryon CEO Ron Cohen founded Acorda and Oryon CMO Burkhard Blank was previously CMO there. Acorda is a historical Parkinson's incumbent with directly relevant commercial infrastructure and provides the most directly comparable prior playbook for Oryon's commercialization strategy.

TypeDirect peer
Description

BlueRock Therapeutics (acquired by Bayer in 2019) is developing iPSC-derived dopaminergic neuron cell therapies for Parkinson's disease, including bemdaneprocel. It is the most direct competitor to Oryon in autologous/allogeneic iPSC-derived neuron replacement for Parkinson's and represents the leading benchmark for this therapeutic approach.

TypeEmerging player
Description

Century Therapeutics is developing iPSC-derived allogeneic cell therapies for cancer and neurodegenerative diseases, leveraging similar iPSC engineering and differentiation science. Although focused initially on oncology, its iPSC platform and CNS ambitions make it a comparable technology peer for Oryon's autologous iPSC approach.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Oryon Cell Therapies

Oryon Cell Therapies is a clinical-stage biotechnology company developing an autologous dopaminergic neuron replacement therapy for Parkinson's disease, derived from patient iPSCs and implanted into the putamen, currently in a Phase 1b/2a trial at Brigham & Women's Hospital.

What Oryon Cell Therapies does

Oryon Cell Therapies is a privately held, clinical-stage biotechnology company headquartered in Belmont, Massachusetts, founded in 2020 by Ole Isacson, M.D., Ph.D. (Harvard Medical School professor and founding director of the Neuroregeneration Research Institute at McLean Hospital) and Nikola Kojic, M.D., Ph.D. The company is developing an autologous neuron replacement therapy for Parkinson's disease in which patient-derived blood cells are reprogrammed into induced pluripotent stem cells (iPSCs) and differentiated into midbrain dopaminergic neurons that are then surgically implanted into the post-commissural putamen. The autologous design is intended to eliminate the need for chronic immunosuppression, and the unilateral implantation approach used in early cohorts provides an internal control to address placebo effects.

The lead program is in an ongoing Phase 1b/2a clinical trial at Brigham & Women's Hospital/Harvard Medical School in collaboration with the Neuroregeneration Institute at McLean Hospital (Mass General Brigham). Interim data from the first five participants, reported in March 2026, showed 29%-62% reductions in OFF-state MDS-UPDRS Part III motor scores at 6-18 months, sustained improvement beyond six months, no serious adverse events, and DaT-SPECT imaging evidence of greater than a five-fold increase in dopaminergic signal in the transplanted putamen of one participant. Several participants also showed reduced levodopa equivalent daily dose, suggesting decreased dependence on dopamine-replacement medication.

Oryon is pre-revenue and has raised approximately $42 million in total equity and grant funding, including a $21 million Series A tranche closed in March 2026 co-led by Neuro.VC and Byers Capital. The company has no commercial product, no disclosed pricing, and no manufacturing-scale commercial operations; revenue, if any, would only follow regulatory approval and commercialization of the autologous cell therapy. Its go-to-market model is currently oriented around clinical trial execution at academic medical centers, scientific conference presentations, and peer-reviewed publications, with future commercialization expected to target movement disorder specialists at major US academic medical centers. The company had 1-10 employees as of the most recent reporting.

Oryon Cell Therapies firmographics

Firmographics
Name
Oryon Cell Therapies
Legal name
Oryon Cell Therapies
Website
https://oryoncelltherapies.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
1–10 employees
Short description
Oryon Cell Therapies is a clinical-stage biotechnology company developing an autologous dopaminergic neuron replacement therapy for Parkinson's disease, derived from patient iPSCs and implanted into the putamen, currently in a Phase 1b/2a trial at Brigham & Women's Hospital.
Ownership category
akta.pro rank

Oryon Cell Therapies industry classification

Industry
Product category
Cell Therapy
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
akta.pro industry
PRIMARYHLAAABAE
Stem Cell Therapies (MSC/iPSC/HSC-derived)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAGAI
Neural & Spinal Cord Regeneration
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering

Keywords

  • Autologous cell therapy
  • Neuron replacement therapy
  • Parkinson's disease treatment
  • Regenerative medicine
  • IPSC-derived neurons

Where Oryon Cell Therapies is headquartered

Location

Headquarters

HQ city
Belmont
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Oryon Cell Therapies business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Future Therapeutic Product Sales: Pre-revenue clinical-stage biotech company. Anticipated future revenue from commercialization of autologous neuron replacement therapy for Parkinson's disease following regulatory approval. Revenue model will likely involve selling cell therapy products directly to healthcare providers and academic medical centers.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

Oryon Cell Therapies product offering

Product offering

Core offering

Oryon Cell Therapies develops an autologous neuron replacement therapy in which a patient's own blood cells are reprogrammed into induced pluripotent stem cells (iPSCs) and differentiated into midbrain dopaminergic neurons for implantation into the putamen to restore motor function in Parkinson's disease patients. The product eliminates the need for chronic immunosuppression and is currently being evaluated in a Phase 1b/2a clinical trial at Brigham & Women's Hospital.

Product overview

Oryon Cell Therapies is a clinical-stage biotechnology company developing a single lead product - an autologous dopaminergic neuron replacement therapy for Parkinson's disease. The therapy involves deriving induced pluripotent stem cells (iPSCs) from the patient's own blood cells, differentiating them into midbrain dopaminergic neurons using proprietary methods, and implanting them directly into the putamen region of the brain to restore dopaminergic function and motor control. The company's technology emerged from 30 years of scientific advances in stem cell biology and neurosurgical techniques, including foundational Parkinson's disease research conducted at Harvard University and Mass General Brigham. The therapy is currently being evaluated in a Phase 1b/2a clinical trial at Brigham & Women's Hospital, with early data demonstrating 29%-62% motor score improvements and neuroimaging evidence of restored dopaminergic signaling.

Differentiator

Problem solved

Functional benefit

Products and services

  • Autologous Dopaminergic Neuron Replacement Therapy (Lead Program) An autologous cell therapy in which a patient's own blood cells are reprogrammed into induced pluripotent stem cells (iPSCs) and differentiated into midbrain dopaminergic neurons for implantation into the post-commissural putamen. The therapy is intended for Parkinson's disease patients to restore dopaminergic signaling and motor function without the need for chronic immunosuppression, and is currently being evaluated in a Phase 1b/2a clinical trial at Brigham & Women's Hospital.

Quantifiable outcome

  • Motor scores decreased 29%–62% from baseline at 6–18 months post-treatment in Phase 1b/2a trial
  • +3 more outcomes

Companies that use Oryon Cell Therapies

Customer profile

Segments2 records

Ideal customer profiles2 records

Oryon Cell Therapies technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Oryon Cell Therapies partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Mass General Brigham - Neuroregeneration Institute at McLean HospitalcoreStrategic or Co-development Partner · 23 March 2026Oryon collaborates with the Neuroregeneration Institute at McLean Hospital, part of Mass General Brigham, for its clinical research program. The collaboration involves foundational Parkinson's disease research and current clinical trial execution. Penelope Hallett, Ph.D., Co-Director of the Neuroregeneration Research Institute, serves as principal investigator.
  • Brigham & Women's HospitalcoreStrategic or Co-development Partner · 23 March 2026Phase 1b/2a clinical trial is being conducted at Brigham & Women's Hospital/Harvard Medical School for Oryon's lead autologous neuron replacement therapy program.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Oryon Cell Therapies competitors and assessment

Company assessment

Emerging players

  • Sana Biotechnology: Sana Biotechnology is developing engineered cell therapies, including hypoimmune cell transplant approaches, with applications in neurological diseases. Although broader than Oryon's focused Parkinson's program, Sana's cell engineering platform and CNS ambitions make it a relevant comparable for autologous/allogeneic cell therapy platforms targeting the brain.
  • Neuron23: Neuron23 is developing precision medicines for Parkinson's disease, including a LRRK2 inhibitor currently in Phase 2. Oryon board member Adam Knight was Neuron23's founder/CEO. Neuron23 competes with Oryon for Parkinson's market share and partnership interest, though via a small-molecule route rather than cell replacement.
  • Cerevel Therapeutics: Cerevel Therapeutics (acquired by AbbVie in 2024) developed CNS therapies including Parkinson's disease candidates (e.g., tavapadon). As a CNS-focused clinical-stage biotech, Cerevel is a relevant comparable for fundraising scale, clinical development approach, and large-pharma acquisition interest in Parkinson's assets.
  • Century Therapeutics: Century Therapeutics is developing iPSC-derived allogeneic cell therapies for cancer and neurodegenerative diseases, leveraging similar iPSC engineering and differentiation science. Although focused initially on oncology, its iPSC platform and CNS ambitions make it a comparable technology peer for Oryon's autologous iPSC approach.

Direct peers

  • Prevail Therapeutics: Prevail Therapeutics (acquired by Eli Lilly in 2020) develops AAV-based gene therapies for neurodegenerative diseases, including PR001 for Parkinson's disease associated with GBA1 mutations. It is a direct competitor addressing Parkinson's neuronal dysfunction via a different modality (gene therapy vs. cell replacement) but the same underlying therapeutic hypothesis.
  • Aspen Neuroscience: Aspen Neuroscience is developing autologous iPSC-derived dopaminergic neuron replacement therapies (ANPD001) for Parkinson's disease. It directly competes with Oryon in the autologous iPSC approach for the same indication, targeting a similar patient population and neurosurgical delivery model.
  • BlueRock Therapeutics: BlueRock Therapeutics (acquired by Bayer in 2019) is developing iPSC-derived dopaminergic neuron cell therapies for Parkinson's disease, including bemdaneprocel. It is the most direct competitor to Oryon in autologous/allogeneic iPSC-derived neuron replacement for Parkinson's and represents the leading benchmark for this therapeutic approach.

Others

  • Roche: Roche has invested in Parkinson's and broader neurodegenerative disease pipelines (including prasinezumab collaborations) and pursues both small-molecule and biologic CNS strategies. Roche represents a relevant large-pharma strategic partner/acquirer with deep neurology presence, rather than a direct competitor to Oryon's cell therapy.

Broad incumbents

  • Vertex Pharmaceuticals: Vertex Pharmaceuticals is advancing VX-880, an allogeneic stem cell-derived islet cell therapy, and is building broader cell therapy capabilities that could overlap with Oryon's CNS cell replacement vision. As a large, well-capitalized biopharma, Vertex represents both a competitive threat and a potential strategic acquirer/partnership candidate.
  • Acorda Therapeutics: Acorda Therapeutics developed and commercialized INBRIJA and other Parkinson's therapies; Oryon CEO Ron Cohen founded Acorda and Oryon CMO Burkhard Blank was previously CMO there. Acorda is a historical Parkinson's incumbent with directly relevant commercial infrastructure and provides the most directly comparable prior playbook for Oryon's commercialization strategy.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Oryon Cell Therapies social profiles

Digital presence

Oryon Cell Therapies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Oryon Cell Therapies leadership team

Management profile

Number of profiles

Profiles6 records

Oryon Cell Therapies funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Oryon Cell Therapies M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Oryon Cell Therapies

What does Oryon Cell Therapies do?

Oryon Cell Therapies develops an autologous neuron replacement therapy in which a patient's own blood cells are reprogrammed into induced pluripotent stem cells (iPSCs) and differentiated into midbrain dopaminergic neurons for implantation into the putamen to restore motor function in Parkinson's disease patients. The product eliminates the need for chronic immunosuppression and is currently being evaluated in a Phase 1b/2a clinical trial at Brigham & Women's Hospital.

Is Oryon Cell Therapies a public or private company?

Oryon Cell Therapies is a private company. It is classified as venture growth investor backed and is currently operating.

When was Oryon Cell Therapies founded?

Oryon Cell Therapies was founded in 2020. It employs 1 to 10 people.

Where is Oryon Cell Therapies based?

Oryon Cell Therapies is headquartered in Belmont, United States, in the North America region.

How does Oryon Cell Therapies make money?

One revenue line is on record: future Therapeutic Product Sales.

Who are Oryon Cell Therapies's main competitors?

Emerging players on record are Sana Biotechnology, Neuron23, Cerevel Therapeutics and Century Therapeutics. Direct peers are Prevail Therapeutics, Aspen Neuroscience and BlueRock Therapeutics. Roche is listed as an others. Broad incumbents are Vertex Pharmaceuticals and Acorda Therapeutics.

Does Oryon Cell Therapies have an API?

No public API is recorded for Oryon Cell Therapies.

What industry is Oryon Cell Therapies in?

Oryon Cell Therapies's product category is Cell Therapy. Its primary akta.pro industry code is HLAAABAE, Stem Cell Therapies (MSC/iPSC/HSC-derived), with a secondary code of HLAAAGAA, Stem Cell–Based Regenerative Therapies. Its NAICS code is 541714.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinancialContent Business PageOryon Cell Therapies Appoints Kenny Choi, Ph.D. as Chief Technical OfficerOryon Cell Therapies announced the appointment of Kenny Choi, Ph.D., as Chief Technical Officer, tasked with leading technical operations and CMC strategy, including transferring its autologous iPSC-derived dopaminergic neuron therapy manufacturing from Mass General Brigham to Oryon's own facilities. Choi brings over 15 years of experience, having contributed to more than a dozen INDs and three BLAs, and previously served as Vice President, CMC at Arcellx. Oryon's lead program is in a Phase 1/2a Parkinson's trial.MorningstarOryon Cell Therapies Appoints Kenny Choi, Ph.D. as Chief Technical OfficerOryon Cell Therapies appointed Kenny Choi, Ph.D., as Chief Technical Officer to lead technical operations and CMC strategy. He will oversee transfer of manufacturing for its autologous iPSC-derived dopaminergic neuron therapy from Mass General Brigham to Oryon's facilities. The company's lead program is in a Phase 1/2a trial for Parkinson's disease.citybizOryon Cell Therapies Names Burkhard Blank Chief Medical Officer to Advance Parkinson’s PrograOryon Cell Therapies has appointed veteran drug development executive Burkhard Blank as Chief Medical Officer to lead the advancement of its clinical-stage cell therapy program for Parkinson's disease. Blank joins from MannKind Corporation and brings regulatory experience including approvals for INBRIJA at Acorda Therapeutics and international programs at Boehringer Ingelheim. The company is currently conducting a Phase 1/2a study with early interim data showing improvements in motor function and imaging evidence consistent with restored dopaminergic signaling.RegmednetCell therapy weekly: biotech emerges from stealth with Parkinson’s disease programOryon Cell Therapies emerged from stealth with Phase Ib/IIa data showing its autologous neuron replacement therapy for Parkinson's disease was well-tolerated with meaningful motor function improvements, after securing US$21 million in funding bringing total funding to US$42 million. Gilead Sciences announced it will acquire Ouro Medicines to add a BCMAxCD3 bispecific T-cell engager for autoimmune diseases to its portfolio, while Siren Biotechnology received FDA IND clearance for a gene therapy targeting high-grade glioma. These developments were presented at the AD/PD™ 2026 International Conference in Copenhagen, Denmark.FinSMEsOryon Cell Therapies Raises $21M in New Series A TrancheOryon Cell Therapies, a Belmont, MA-based clinical-stage biotechnology company, closed a $21M tranche of Series A financing from investors including Neuro.VC and Byers Capital, bringing total equity and grant funding to $42M. The funds will support completion of an ongoing Phase 1b/2a clinical trial of its autologous neuron replacement therapy for Parkinson's disease and preparations for a Phase 3 trial. The company also announced the appointment of Ron Cohen, M.D. as Chief Executive Officer.Pulse 2.0Oryon Cell Therapies: $42 Million Raised For Autologous Neuron Replacement Therapies Targeting Parkinson’s DiseaseOryon Cell Therapies emerged from stealth with $42 million in total funding, including a $21 million Series A tranche backed by Neuro.VC and Byers Capital, to advance its autologous neuron replacement therapy for Parkinson's disease through Phase 1b/2a clinical trials. The company, which appointed former Acorda Therapeutics CEO Ron Cohen as its new leader, uses induced pluripotent stem cells derived from a patient's own blood to generate dopaminergic neurons for brain implantation, with early clinical data demonstrating motor improvements and restored dopaminergic signaling. The funding will support trial completion, manufacturing scale-up, and regulatory preparations for a potential Phase 3 trial.BioSpaceOryon Splashes Onto Parkinson’s Scene With $42M for Cell TherapyOryon Cell Therapies, a Massachusetts-based biotech, has secured $42 million in capital including a recently closed $21 million Series A tranche to advance its autologous cell therapy for Parkinson's disease. Interim Phase 1b/2a data from five treated patients showed substantial motor function improvements of 29% to 62% from baseline at 6 to 18 months, along with marked increases in dopaminergic signaling and reduced levodopa dependence. The company plans to use the funding to scale up manufacturing capacity ahead of Phase 3 development.citybizOryon Cell Therapies Raises $21M, Total Funding Reaches $42MOryon Cell Therapies, a clinical-stage biotechnology company developing autologous neuron replacement therapies for Parkinson’s disease and other neurodegenerative disorders, has emerged from stealth and closed a $21 million tranche of Series A financing, bringing its total equity and grant funding to $42 million. The funding round, joined by investors including Neuro.VC and Byers Capital, will support completion of an ongoing Phase 1b/2a clinical trial and manufacturing scale-up for advancement to a Phase 3 trial. The company also appointed Ron Cohen, M.D., former CEO and founder of Acorda Therapeutics, as its new CEO.AijournOryon Cell Therapies Reports Phase 1b/2a Data Showing Sustained Motor Improvements in People with Parkinson’s DiseaseOryon Cell Therapies announced positive Phase 1b/2a clinical trial data for its autologous dopaminergic neuron replacement therapy for Parkinson's disease, showing sustained motor improvements and neuroimaging evidence of restored dopaminergic signaling in participants. The first five participants demonstrated 29%–62% reductions in motor scores at 6–18 months post-treatment, with DaT-SPECT imaging in one patient showing more than five-fold increase in dopaminergic signal in the implanted putamen. The company, in collaboration with Mass General Brigham's Neuroregeneration Institute at McLean Hospital, plans to begin bilateral implantations in a second cohort this quarter.AijournOryon Cell Therapies Emerges From Stealth Focusing on Autologous Neuron Replacement Therapies for Parkinson’s Disease and Other Neurodegenerative DisordersOryon Cell Therapies, a clinical-stage biotechnology company, emerged from stealth with a $21 million Series A funding tranche, bringing its total financing to $42 million, and appointed Ron Cohen, M.D. as Chief Executive Officer. The company's lead neuron replacement therapy for Parkinson's disease demonstrated motor improvements and neuroimaging evidence of restored dopaminergic signaling in early data from an ongoing Phase 1b/2a clinical trial. The financing will support completing the Phase 1b/2a trial and funding manufacturing scale-up and regulatory engagement ahead of a planned Phase 3 trial.